Blueprint Medicines (BPMC) Misses Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.86), $0.07 worse than the analyst estimate of ($0.79).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
